ERBB2 and breast cancer: Our results not only enhance the prominent role of pertuzumab added to dual anti-HER2 targeted therapies in the (neo)adjuvant treatment of HER2+ breast cancer but also alleviated some of the confusion regarding the benefit of adding pertuzumab to HER2 therapies and effectively revealed the importance of individualized therapy.